Skip to main content

Table 1 Characteristics of the study population according to the Pro12Ala genotype

From: The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes

  Pro/Pro (N =212) ProAla (N = 44)
Males (%) 119 (56.1) 23 (52.3)
Age (years) 60.9 ± 4.1 60.3 ± 5.7
BMI (Kg/m2) 29.4 ± 4.0 29.6 ± 4.5
HB1Ac (%) 7.0 ± 1.5 6.9 ± 0.9
Systolic BP (mmHg) 135.3 ± 18.6 133.0 ± 27.6
Diastolic BP (mmHg) 78.4 ± 8.3 78.7 ± 15.9
Diabetes duration (years) 7.4 ± 6.3 8. 2 ± 7.3
Smokers (%) 49 (23.1) 11 (25)
With Rethinopathy (%) 49 (23.1) 12 (27.3)
Treated with diet (%) 20 (9.6) 5 (11.9)
Treated with oral agents (%) 138 (66) 29 (69.1)
Treated with insulin (%) 51 (24.4) 8 (19)
Treated with ACE or ARB (%) 155 (73.1) 29 (65.9)
Treated with Statins (%) 131 (61.8) 21 (47.7)
Microalbuminuria (%) 62 (29.2) 10 (22.7)
Macroalbuminuria (%) 8 (3.8) 2 (4.5)
GFR < 60 ml/min/ 1.73 m2 (%) 14 (6.7) 3 (7)
  1. BP: Blood pressure UAER: Urinary albumin excretion rate; GFR: glomerular filtration rate.